Change - Announcement of Cessation::Retirement of Executive Vice President and Vice President of Research and Development

Issuer & Securities

Issuer/ Manager
QT VASCULAR LTD.
Securities
QT VASCULAR LTD. - SG2G82000008 - 5I0
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
15-Jan-2021 18:08:05
Status
New
Announcement Sub Title
Retirement of Executive Vice President and Vice President of Research and Development
Announcement Reference
SG210115OTHRI7JX
Submitted By (Co./ Ind. Name)
Eitan Konstantino
Designation
Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
Announcement on the retirement of Maria Pizarro as Executive Vice President and Vice President of Research and Development.

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms Gillian Goh, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

Additional Details

Name Of Person
Maria Pizarro
Age
59
Is effective date of cessation known?
Yes
If yes, please provide the date
31/12/2020
Detailed Reason (s) for cessation
Ms Maria Pizarro has decided to retire.

After having interviewed Ms Maria Pizarro and to the best of its knowledge, the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd., is satisfied that save as disclosed in this announcement, there are no material reasons for the retirement of Ms Maria Pizarro as the Company's Executive Vice President and Vice President of Research and Development.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
01/01/2007
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
1
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
2
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Vice President
Vice President of Research and Development
Role and responsibilities
As a key member of the executive management team, Ms Maria Pizarro reported to the CEO and was responsible for establishing the Company's technical vision and leading all aspects of the product development based on strategies decided by the Board. As Vice President of Research and Development, she was responsible for the Company's development plans and technologies, which includes the planning and management of product development projects for medical devices in support of the Company's strategic plan, the definition of product requirements and specifications and the planning and execution of projects for the Company.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil.
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
5,681,696 Options.
1,643,536 Shares.
Past (for the last 5 years)
Nil
Present
Nil